PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Latest Episodes:

Lipika Goyal, MD, MPhil / Riad Salem, MD, MBA - The Convergence of Interventional Radiologists and Oncologists in HCC: Shared Decision-Making and Care Coordination at the Center of Personalized Care Across the Disease Apr 17, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FYP865. CME credit will be available until April 26, 2025.

The Convergence of Interventional Radiologists and Oncologists in HCC: Shared Decision-Making and Care Coordination at the Center of Personalized Care Across the Disease Continuum

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Eisai Inc.

Disclosure information is available at the beginning of the video presentation.

Richard K. Bogan, MD, FCCP, FAASM - Navigating Narcolepsy in Family Practice: Patient-Centered Strategies to Optimize the Experience and Outcomes of Treatment Apr 17, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/UVZ865. CME/MOC credit will be available until April 9, 2025.

Navigating Narcolepsy in Family Practice: Patient-Centered Strategies to Optimize the Experience and Outcomes of Treatment

Support
This activity is supported by an educational grant from Avadel CNS Pharmaceuticals, LLC.

Disclosure information is available at the beginning of the video presentation.

Prof. Dr. med. Stephan Stilgenbauer - Finite Therapy, Infinite Possibilities in CLL: Exploring the Rapid Emergence of Newer Time-Limited BTKi Combinations Apr 10, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CPD information, and to apply for credit, please visit us at PeerView.com/BGH865. CME/MOC/CPD credit will be available until April 18, 2025.

Finite Therapy, Infinite Possibilities in CLL: Exploring the Rapid Emergence of Newer Time-Limited BTKi Combinations

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure information is available at the beginning of the video presentation.

Javier Morales, MD, FACP, FACE - Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal Mar 28, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/WMV865. CME/NCPD/AAPA credit will be available until March 25, 2025.

Conversations With Peers About T2DM: Best Practices for Optimizing Treatment Using Weight Management as a Primary Goal

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

Sergio A. Giralt, MD, FACP - Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance Strategies Mar 28, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/AJC865. CME/NCPD credit will be available until March 25, 2025.

Reinforcing the “Bridge” to HCT in AML: Clinical Conversations on Augmenting Efficacy With Innovative Options as Pre-Transplant and Maintenance Strategies

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by independent educational grants from Actinium Pharmaceuticals, Astellas, and Jazz Pharmaceuticals, Inc.

Disclosure information is available at the beginning of the video presentation.

Krina Patel, MD, MSc - Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses and Enduring Efficacy Mar 27, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/QQW865. CME/NCPD credit will be available until March 21, 2025.

Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses & Enduring Efficacy

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported through independent medical educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

Disclosure information is available at the beginning of the video presentation.

Zack DeFilipp, MD - Closing the Treatment Gap in Acute and Chronic GVHD: Improving Post-HCT Outcomes With Innovative Targeted Approaches Mar 27, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/TGK865. CME/MOC credit will be available until March 20, 2025.

Closing the Treatment Gap in Acute and Chronic GVHD: Improving Post-HCT Outcomes With Innovative Targeted Approaches

Support
This activity is supported by an educational grant from Incyte Corporation.

Disclosure information is available at the beginning of the video presentation.

Roy F. Chemaly, MD, MPH, FIDSA, FACP / Genovefa Papanicolaou, MD, FIDSA, Fellow ASCT - Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral Agents Mar 27, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/WAV865. CME/NCPD credit will be available until March 25, 2025.

Cracking Down on Post-Transplant CMV: Guidance on Sequential Treatment With Newer Antiviral Agents

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure information is available at the beginning of the video presentation.

Prof. Mohamad Mohty, MD, PhD / Christine N. Duncan, MD - Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized Management Mar 27, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD information, and to apply for credit, please visit us at PeerView.com/EJG865. CME/NCPD credit will be available until March 20, 2025.

Canceling the Cascade of VOD/SOS: Team-Based Prophylaxis, Diagnosis, and Customized Management

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Disclosures
Prof. Mohamad Mohty, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.
Honoraria from Adaptive Biotechnologies; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; Stemline Therapeutics, Inc.; and Takeda Pharmaceutical Company.

Christine N. Duncan, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for bluebird bio, Inc.; Jazz Pharmaceuticals, Inc.; and Omeros Corporation.

Medical Director
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Sandip Patel, MD - The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC Mar 27, 2024

Show notes

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/JSU865. CME/MOC credit will be available until March 22, 2025.

The “Immunosurge” Continues: Moving in Leaps and Bounds to Expand the Role and Impact of Immunotherapy in Metastatic, Locally Advanced, and Early-Stage NSCLC

Support
This activity is supported by an independent educational grant from AstraZeneca.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Sandip Patel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Certis USA L.L.C.; Genentech, Inc.; Illumina, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Natera, Inc.; Pfizer Inc.; and Tempus.
Grant/Research Support from Amgen Inc; AstraZeneca/MedImmune, Inc.; A2BIO; Bristol Myers Squibb; Fate Therapeutics; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; IOVANCE Biotherapeutics, Inc.; Lilly; Merck & Co., Inc.; and Pfizer Inc.

Faculty/Planner
Tina Cascone, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Genentech, Inc.; Merck & Co., Inc.; Pfizer Inc.; and Regeneron Pharmaceuticals Inc.
Grant/Research Support from AstraZeneca and Bristol Myers Squibb.

Faculty/Planner
John V. Heymach, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; ArriVent Biopharma; AstraZeneca; BioCurity Pharmaceuticals; BioNTech SE; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Curio Science; DAVA Oncology; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; IDEOlogy Health; Immunocore Ltd; Janssen Biotech; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; RefleXion; Regeneron Pharmaceuticals Inc.; Sandoz Group AG; sanofi-aventis U.S. LLC; Spectrum Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; uniQure NV; and Venn Biosciences.
Grant/Research Support from AstraZeneca; Boehringer Ingelheim International GmbH; Spectrum Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Bristol Myers Squibb; and Takeda Pharmaceutical Company Limited.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.